Haleon Pakistan Limited (PSX:HALEON)

Market Cap	95.56B
Revenue (ttm)	39.28B
Net Income (ttm)	5.28B
Shares Out	117.05M
EPS (ttm)	45.08
PE Ratio	18.11
Forward PE	n/a
Dividend	20.00 (2.50%)
Ex-Dividend Date	Mar 11, 2025

Volume	168,917
Average Volume	79,028
Open	800.45
Previous Close	799.75
Day's Range	800.45 - 838.44
52-Week Range	285.00 - 975.00
Beta	0.37
RSI	63.56
Earnings Date	Aug 28, 2025

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 450
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.